Skip to content

BBNX BBNX Operating Cash Flow

Operating Cash Flow at other companies

Insulet logo
InsuletPODD
$113.8M+78.4%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$11.05M+160%
Medtronic logo
MedtronicMDT
$2.57B+1.8%
AdaptHealth logo
AdaptHealthAHCO
$93.72M-1.9%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$180.08M+16.8%

Other financials

Income statement

See full
Revenue$27.6M+56.6%
Gross profit$16.4M+83.2%
Operating income-$24.3M-30.2%
Net income-$21.9M+23.6%
EPS (diluted)-$0.49+47.3%

Balance sheet

See full
Cash & equivalents$30.2M-28.9%
Total debt$6.9M-0.9%
Total equity$271.2M-13.5%
Total assets$304.4M-9.9%

Cash flow

See full
CapEx$1.4M+314%
Free cash flow-$25.2M-24.1%

Valuation

See full
Market cap$708.98M-8.6%
Enterprise value$685.68M
P/S6.4×

Profitability

See full
Gross margin57.2%+3.2pp
Operating margin-70.1%-6.4pp
Net margin-60.3%-17.4pp
FCF margin-55.4%-14.3pp

Returns & leverage

See full
Return on equity-22.7%
Debt / equity0.0×
Current ratio10.7×-5.2×

Where this comes from

Reported directly by BBNX in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: BBNX’s 10-Q, filed April 21, 2026, on SEC EDGAR. View the filing →

Ask your AI about BBNX's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BBNX's operating cash flow?
BBNX (BBNX) reported operating cash flow of -$23.83M in Q1 2026.
How has BBNX's operating cash flow changed year-over-year?
BBNX's operating cash flow decreased by 19.3% year-over-year, from -$19.98M to -$23.83M.
What is the long-term trend for BBNX's operating cash flow?
Over 2 years (2023 to 2025), BBNX's operating cash flow has grown at a 25.3% compound annual growth rate (CAGR), from -$32.45M to -$50.93M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.